Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Canadian Cancer Trials Group
University of Texas Southwestern Medical Center
Astellas Pharma Inc
Massachusetts General Hospital
OBI Pharma, Inc
Rigshospitalet, Denmark
Mayo Clinic
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Astellas Pharma Inc
Astellas Pharma Inc
Hunan Province Tumor Hospital
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Genentech, Inc.
M.D. Anderson Cancer Center
Hunan Province Tumor Hospital
Hospital Israelita Albert Einstein
Fondazione per la Medicina Personalizzata
Syndax Pharmaceuticals
Eisai Inc.
Rush University Medical Center
M.D. Anderson Cancer Center
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI)
Fox Chase Cancer Center
Samsung Medical Center
Samsung Medical Center
Tata Memorial Hospital
National Cancer Center, Korea
National Cancer Center, Korea
SCRI Development Innovations, LLC
Shanghai Changzheng Hospital
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Translational Oncology Research International
M.D. Anderson Cancer Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Oslo University Hospital
Spectrum Pharmaceuticals, Inc
Barbara Ann Karmanos Cancer Institute
Intergroupe Francophone de Cancerologie Thoracique
Hoffmann-La Roche
Odense University Hospital
AVEO Pharmaceuticals, Inc.